Phase III data in The Lancet show significant benefit of Novartis drug ... International Business Times (press release) 10, 2013 /PRNewswire/ -- Data published today in The Lancet showed that patients on AfinitorĀ® (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a ... |
